Multi-Targeted Kinase Inhibition Alleviates Mtor Inhibitor
Total Page：16
File Type：pdf, Size：1020Kb
Breast Cancer Research and Treatment https://doi.org/10.1007/s10549-019-05380-z PRECLINICAL STUDY Multi‑targeted kinase inhibition alleviates mTOR inhibitor resistance in triple‑negative breast cancer Jichao He1 · Ronan P. McLaughlin1 · Vera van der Noord1 · John A. Foekens2 · John W. M. Martens2 · Gerard van Westen1 · Yinghui Zhang1 · Bob van de Water1 Received: 21 February 2019 / Accepted: 27 July 2019 © The Author(s) 2019 Abstract Purpose Owing to its genetic heterogeneity and acquired resistance, triple-negative breast cancer (TNBC) is not responsive to single-targeted therapy, causing disproportional cancer-related death worldwide. Combined targeted therapy strategies to block interactive oncogenic signaling networks are being explored for efective treatment of the refractory TNBC subtype. Methods A broad kinase inhibitor screen was applied to profle the proliferative responses of TNBC cells, revealing resist- ance of TNBC cells to inhibition of the mammalian target of rapamycin (mTOR). A systematic drug combination screen was subsequently performed to identify that AEE788, an inhibitor targeting multiple receptor tyrosine kinases (RTKs) EGFR/ HER2 and VEGFR, synergizes with selective mTOR inhibitor rapamycin as well as its analogs (rapalogs) temsirolimus and everolimus to inhibit TNBC cell proliferation. Results The combination treatment with AEE788 and rapalog efectively inhibits phosphorylation of mTOR and 4EBP1, relieves mTOR inhibition-mediated upregulation of cyclin D1, and maintains suppression of AKT and ERK signaling, thereby sensitizing TNBC cells to the rapalogs. siRNA validation of cheminformatics-based predicted AEE788 targets has further revealed the mTOR interactive RPS6K members (RPS6KA3, RPS6KA6, RPS6KB1, and RPS6KL1) as synthetic lethal targets for rapalog combination treatment. Conclusions mTOR signaling is highly activated in TNBC tumors. As single rapalog treatment is insufcient to block mTOR signaling in rapalog-resistant TNBC cells, our results thus provide a potential multi-kinase inhibitor combinatorial strategy to overcome mTOR-targeted therapy resistance in TNBC cells. Keywords Multi-kinase inhibitor · mTOR-targeted therapy · Drug resistance · Triple-negative breast cancer (TNBC) · Polypharmacology Abbreviations FC Fold change BL Basal-like IC50 Half-maximal inhibitory concentration CDK4 Cyclin-dependent kinase 4 IM Immunomodulatory CI Combination index KI Kinase inhibitor EGF Human epidermal growth factor LAR Luminal androgen receptor-like MSL Mesenchymal stem-like mTOR The mammalian target of rapamycin Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s1054 9-019-05380 -z) contains RTK Receptor tyrosine kinase supplementary material, which is available to authorized users. SRB Sulforhodamine B TNBC Triple-negative breast cancer * Bob van de Water [email protected] 1 Division of Drug Discovery and Safety, Leiden Background Academic Centre for Drug Research, Leiden University, 2300 RA Leiden, The Netherlands Triple-negative breast cancer (TNBC) constitutes a small 2 Department of Medical Oncology and Cancer Genomic subtype (10–20%) of breast cancer, but causes the major- Netherlands, Erasmus MC Cancer Institute, Erasmus Medical ity of breast cancer-related deaths [1, 2]. As defned by the Centre, 3000 CA Rotterdam, The Netherlands Vol.:(0123456789)1 3 Breast Cancer Research and Treatment absence of ER and PR expression and HER2 overexpression, with mTOR signaling. Most importantly, our study provided TNBC is not curable by hormone receptor or HER2-targeted an efcacious approach for exploring cancer combination therapies [3]. Furthermore, TNBC is highly heterogeneous. treatment. Moreover, the combinatorial therapy is more Gene expression profling has further classifed TNBC into efective than single drug application and thus demonstrates six unique molecular subtypes, namely basal-like (BL1 and a therapeutic advantage over either agents as a monotherapy BL2), mesenchymal (M), mesenchymal stem-like (MSL), in TNBC treatment. immunomodulatory (IM), and luminal androgen receptor- like (LAR) subtype [4]. The TNBC molecular signatures have been explored for targeted therapies in clinical trials, Methods including those targeting receptor tyrosine kinases (RTKs, e.g., EGFR, VEGFR, c-Met), PI3K/AKT, Ras/MAPK, JAK/ Kinase inhibitor library combination screen STAT, cell cycle regulators [5, 6]. Yet, TNBC has not ben- efted from above mono-targeted therapies so far, due to One day post seeding into 96-well plates, cells were treated intrinsic or acquired resistance [6]. with individual kinase inhibitors alone or combined with The mammalian target of rapamycin (mTOR), a con- rapamycin at 1 µM. After 4-day treatment, proliferation was served serine/threonine protein kinase, is a central regulator evaluated by sulforhodamine B (SRB) colorimetric assay of cell growth and proliferation, by sensing and integrating [23]. Detailed information on materials and methods can be multiple signals from growth factors and nutrient signals found in Supplementary fle ESM_3. [7, 8]. mTOR hyperactivity is frequently observed in TNBC compared to other breast cancer subtypes and is often cor- related with poor prognosis, underpinning the potential Results of mTOR-targeted therapy for TNBC treatment [9–11]. Although mTOR-targeted interventions, such as rapamy- TNBC cell lines are diferentially responsive to mTOR cin and its analogs (rapalogs) temsirolimus and everoli- inhibitor rapalogs mus, delay progression and extend survival, patients with TNBC eventually develop resistance to mTOR inhibitors To gain insights into TNBC dependency on mTOR signaling with undesired outcome [9, 12]. Evidence has shown that integration for proliferation and cell survival, a KI library rapalog treatment could release mTOR negative feedback on (Selleckchem®) containing 378 small molecular inhibitors upstream kinases and activate compensatory pathways, for targeting various kinase signaling pathways was screened instance, PI3K/AKT and MAPK/ERK signaling pathways, across 19 TNBC cell lines (Suppl. Table S1), which are thereby bypassing mTOR inhibition [13–15]. This obser- representative for the six transcriptome-based subtypes of vation underscores the need for alternative combinatorial TNBC [4]. All TNBC cell lines were exposed to individual therapeutic approaches for TNBC treatment. inhibitors at 1 µM for 4 days, followed by measurement of Since oncogenic pathways incorporate multiple signaling cell proliferation. The efect of each inhibitor on prolifera- components and axes to promote tumor malignancy, mono- tion was assessed by Z scores normalized to overall pro- therapy may not be sufcient for long-term control of TNBC liferative response. TNBC cell lines were largely resistant [9, 13, 16]. Hence, simultaneously targeting diferent sign- to the majority of the kinase inhibitors, without any clear aling molecules represents a promising strategy to impede correlation to the TNBC molecular subtypes (Fig. 1a). The tumor growth and progression [8, 17]. Several reports have proliferative response towards mTOR inhibitors was vari- documented that co-targeting growth factor receptors and able among TNBC cell lines. We distinguished 11 TNBC mTOR exerts cooperative anti-cancer efects in various can- cell lines insensitive to diferent mTOR inhibitors (Fig. 1b), cer types, including TNBC [18–22]. However, these studies including rapamycin (Rap) and its analogs (i.e., rapalogs), focus on a particular combination in the questioned cancer zotarolimus, everolimus, ridaforolimus, and temsirolimus. type. Little is known about the interactive kinases involved HCC1806 and SUM149PT were most resistant to rapologs, in rapalog resistance and the mechanisms of the combinato- while Hs578T was most sensitive. rial efect remain unclear. Here, we systematically screened Rapalogs are highly selective allosteric inhibitors of a broad collection of kinase inhibitors across a large panel of mTOR, by binding to FKBP12/rapamycin-binding domain TNBC lines treated with rapamycin. Our data demonstrated to block mTOR Ser2448 phosphorylation and function [24, that multiple targeted kinase inhibition, for instance, by 25]. mTOR Ser2448 is a predominant phosphorylation inhibitor AEE788, sensitizes TNBC cells to various mTOR residue for mTOR kinase activity in response to mitogen- inhibitors, rapamycin, temsirolimus, and everolimus. Inte- derived stimuli [25]. Therefore, we examined the inhibi- grated cheminformatics study and siRNA validation revealed tory efect of rapamycin (Rap), temsirolimus (Tem), and additional putative targets of AEE788, which interact closely everolimus (Eve), on Ser2448-mTOR phosphorylation with 1 3 Breast Cancer Research and Treatment A TNBC Subtype LAR BL1 BL2 C Rap Tem Eve D Rap Tem Eve MSL M unclassified M M M M M M M M M M M M 1µ 1µ 1µ 1µ 1µ 1µ 0.1µ 0.1µ 0.1µ 0.1µ 0.1µ 0.1µ Pathway DMSO DMSO Angiogenesis 0.01µM 0.01µM 0.01µM 0.01µM 0.01µM 0.01µM Autophagy 1.5 Cell Cycle p-mTOR Cytoskeletal Signaling DNA Damage 1.0 Epigenetics mTOR GPCR & G Protein JAK/STAT 0.5 HCC1806 MAPK Tubulin NF-κB p-mTOR / mTOR 0.0 Others HCC1806 PI3K/AKT/mTOR 1.5 Protein Tyrosine Kinase p-mTOR TGF-β/Smad T 7 y 1.0 T T E E E Z score 49P mTOR 4 BT20 M1 thwa BT549 2 0.5 HCC38 SKBR HCC70 Hs578T SU Pa 0 Tubulin HCC1806 HCC1937 HCC1143 A-MB-468 A-MB-453 A-MB-231 A-MB-436 SUM52P −2 p-mTOR / mTOR SUM149P SUM159P SUM229P SUM185P −4 0.0 MD MD MD MD SUM149PT SUM1315MO2 1.5 p-mTOR B mTORi T 1.0 Zotarolimus mTOR Rapamycin Everolimus Hs578